New England Biolabs introduces a tunable T7 expression strain for challenging proteins
Lemo21(DE3) is the first commercial product from NEB based on the Lemo System™, a technology developed by Xbrane Bioscience, a company originating from the Center for Biomembrane Research at Stockholm University. NEB and Xbrane Bioscience recently announced an agreement in which NEB would commercialize products based on the Lemo System through its international distribution network. Additionally, the technology is available for licensing by both companies.
Lemo21(DE3) Competent E. coli is being launched at the Pep Talk 2010 Protein Expression Conference, January 12-15, 2010 in San Diego, CA.
For more information, visit www.neb.com.